KyriakosPeterPapadopoulosMD

Oncology • San Antonio, TX

Senior Clinical Investigator at START in San Antonio

Join to view full profile

Are you Dr. Papadopoulos?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 60 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
4383 Medical Dr
San Antonio, TX 78229
Phone+1 210-593-5700

Fax+1 210-593-5992
Is this information wrong?

Summary

Dr. Kyriakos Papadopoulos, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and New York. He is affiliated with Methodist Hospital and Northeast Baptist Hospital.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 1999
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1994 - 1997
University of the WitwatersrandClass of 1985

Certifications & Licensure

TX State Medical License 2004 - 2025
NY State Medical License 1997 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2001 Apr 01
Terminated
Phase 1
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma Start of enrollment: 2001 Oct 01
Unknown status
Phase 1
Study of NMS-1116354 in Solid Tumors Start of enrollment: 2009 Apr 01
Terminated
Phase 1
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Study of DS-2248 in Participants With Advanced Solid Tumors Start of enrollment: 2011 Mar 29
Terminated
Phase 1
Study of PM060184 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
Active, not recruiting
Phase 1
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Start of enrollment: 2016 Feb 01
Recruiting
Phase 1
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression Start of enrollment: 2017 May 18
Terminated
Phase 1
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Start of enrollment: 2017 Sep 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, David F McDermott, M Dror Michaelson, Leonard J Appleman, Ananya Roy, Rodolf...> ;European Journal of Cancer. 2024 Jan 1
6 citations
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, ...> ;Cancer Discovery. 2023 Nov 1
3 citations
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced gliob...
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Young Kwang Chae, Jyoti D Patel, Einat Shacham-Shmueli, Karen Kelly, ...> ;Neuro-Oncology Advances. 2022 Dec 21
4 citations
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Timothy A Yap, Patricia M LoRusso, Deborah J Wong, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leun...> ;Clinical Cancer Research. 2023 Mar 1
90 citations
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With AdvancedSolid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve, Lyudmila Bazhenova, Melissa L Johnson, Karen L Velastegui, Cornelius...> ;Journal of Clinical Oncology. 2022 Aug 10
15 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
4 citations
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Amita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, Drew W Rasco, Naomi B Haas, Hirak Der-Torossian, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Manal Tawashi...> ;Targeted Oncology. 2022 Mar 1
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Amita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, Drew W Rasco, Naomi B Haas, Hirak Der-Torossian, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Manal Tawashi...> ;Targeted Oncology. 2022 Mar 1
2 citations
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, San...> ;Nature Medicine. 2021 Aug 27
30 citations
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Wael A. Harb, Cody J. Peer, Qiong Hua, Siying Xu, Haolan Lu, Ni Lu, Yue He, Ting Xu, Ruiping Dong, John Gong, David T.L. Liu> ;The Oncologist. 2021 Sep 1
12 citations
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Nec...
Hani M. Babiker, Irene Brana, Daruka Mahadevan, Taofeek K. Owonikoko, Emiliano Calvo, Danny Rischin, Victor Moreno, Kyriakos P. Papadopoulos, Marka R. Crittenden, Silv...> ;The Oncologist. 2021 Sep 1
9 citations
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data fr...
Victor Moreno, Pilar Garrido, Kyriakos P. Papadopoulos, Maria Jose De Miguel Luken, Marta Gil-Martin, Raid Aljumaily, Lee S. Rosen, P. Rietschel, Kosalai Kal Mohan, Su...> ;Lung Cancer. 2021 May 1
126 citations
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, San...> ;Nature Medicine. 2021 Apr 22
22 citations
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen, Richard Wnek, Georgina V. Long> ;Clinical Cancer Research. 2021 Apr 1
7 citations
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.
Anne Paccaly, Michael R. Migden, Kyriakos P. Papadopoulos, Feng Yang, John D. Davis, Ronda Rippley, Israel Lowy, Matthew G. Fury, Elizabeth Stankevich, Danny Rischin> ;Advances in Therapy. 2021 Mar 25
15 citations
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final res...
Nizar M. Tannir, Kyriakos P. Papadopoulos, Deborah J. Wong, Raid Aljumaily, Annie Hung, Manuel Afable, Jong Seok Kim, David Ferry, Alexandra Drakaki, Johanna C. Bendel...> ;International Journal of Cancer. 2021 Mar 12
46 citations
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martín, Irene Brana, June Y. Hou, Daniel Cho, Gerald Steven Falchook, Silvia C. Formenti, Salma K. Jabbour, Kathleen ...> ;Gynecologic Oncology. 2020 Nov 1
57 citations
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Ryan Abdul Razak, James M. Cleary, Victor Moreno, Michael Boyer, Emilliano Calvo Aller, William Jeffery Edenfield, Jeanne Tie, R. Donald Harvey, Annemie Rutte...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
4 citations
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Kyriakos P. Papadopoulos, Nehal Lakhani, Gerald Steven Falchook, Gosia Riley, Johan Baeck, Karen S. Brown, Gilad Gordon, Lidya Le, Judy S. Wang> ;Cancer Immunology, Immunotherapy. 2021 Mar 1
49 citations
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. S...> ;Clinical Cancer Research. 2020 Sep 15
8 citations
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
J. Randolph Hecht, Kyriakos P. Papadopoulos, Gerald Steven Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, Deborah J. Wong, Karen A. Autio, Zev A. Wainb...> ;Investigational New Drugs. 2021 Feb 1
21 citations
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in ...
Aung Naing, Joseph Paul Eder, Sarina Anne Piha-Paul, Claude Gimmi, Elizabeth Hussey, Sen Zhang, Vera Hildebrand, Vinayak Hosagrahara, Christina Habermehl, Jacques Mois...> ;Journal for Immunotherapy of Cancer. 2020 Aug 1
41 citations
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.
Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert C. Lockhart, Kathleen N. Moore, Gerald Steven Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Le...> ;Clinical Cancer Research. 2020 Mar 1
21 citations
A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma.
Monica M. Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold N. Keer, Aram Oganesian, Xiang Yao Su, Simon...> ;Clinical Cancer Research. 2020 Jan 3
632 citations
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D. Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R. Baer, Joshua Ballard, Michael Bur...> ;Cancer Discovery. 2020 Jan 1
Join now to see all

Press Mentions

START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
FDA Grants Cemiplimab Breakthrough Designation for CSCCSeptember 8th, 2017
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual MeetingJune 4th, 2017
Join now to see all

Hospital Affiliations

Methodist HospitalSan Antonio, Texas
Northeast Baptist HospitalSan Antonio, Texas